Atlas Trials

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Clinical trial NCT03362814 · COMPLETED

Trial details

NCT number
NCT03362814
Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
HCV
Start date
2017-07-01
Primary completion
2018-12-12
Enrollment
425

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.